Africa: The Journey Towards an Aids Vaccine

[Key Correspondents] The International AIDS Vaccine Initiative (IAVI) has published a report highlighting several milestones in the journey towards an AIDS vaccine.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

We previously reported that four doses or four double doses of hepatitis B vaccination regimens could not significantly increase a response rate compared with standard doses. However, the antibody levels were ...
Source: AIDS Research and Therapy - Category: Infectious Diseases Authors: Tags: Short Report Source Type: research
This study sought to assess the knowledge of HIV among older adults (50  years and ...
Source: BMC Geriatrics - Category: Geriatrics Authors: Tags: Research article Source Type: research
CONCLUSIONS: Despite the highly effectiveness of the standard hepatitis B vaccination regimen at 6 months after completion, the long-term immunogenicity was lower than the four double doses regimen among HIV-infected adults with CD4+ cell counts > 200 cells/mm3 and undetectable plasma HIV-1 RNA. The standard vaccination regimen may not be the best strategy to provide long-term immune response against hepatitis B virus among HIV-infected individuals. Trial registration NCT1289106, NCT02713620. PMID: 31711528 [PubMed - in process]
Source: AIDS Research and Therapy - Category: Infectious Diseases Authors: Tags: AIDS Res Ther Source Type: research
This study demonstrates the need to develop and disseminate educational programs for dental providers so they can assist with efforts to raise HPV vaccination rates. PMID: 31690468 [PubMed - as supplied by publisher]
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Abstract Acquired Immunodeficiency Syndrome (AIDS), caused by Human Immunodeficiency virus (HIV), is a life-threatening disorder that persists worldwide as a severe health problem. Since it was connected with HIV attachment process, the Chemokine receptor CCR5 has been at the development leading edge of several gene-based therapies. Given the shortcomings of the current anti-retroviral treatment procedure and the non-availability of a licensed vaccine, the aptitude to modify complex genomes with Designer Nucleases has had a noteworthy impact on biotechnology. Over the last years, ZFN, TALEN and CRISPR/Cas9 gene-ed...
Source: Current HIV Research - Category: Infectious Diseases Authors: Tags: Curr HIV Res Source Type: research
A 25 year-old tuberculosis patient is treated at her home in Funafuti, the main island of Tuvalu in the South Pacific. Credit: UNDP Tuvalu/Aurélia Rusek.By External SourceUNITED NATIONS, Oct 17 2019 (IPS) A staggering 1.5 million people died from tuberculosis (TB) last year, the UN health agency said on Thursday, in an appeal for far greater funding and political support to eradicate the curable and preventable disease. Caused by the bacteria Mycobacterium tuberculosis, TB commonly causes persistent coughing, fatigue and weight loss. According to the World Health Organization (WHO) and its latest Global TB Report, a...
Source: IPS Inter Press Service - Health - Category: International Medicine & Public Health Authors: Tags: Global Headlines Health Poverty & SDGs Source Type: news
Publication date: December 2019Source: Microbial Pathogenesis, Volume 137Author(s): Faruq Abdulla, Utpal Kumar Adhikari, M. Kamal UddinAbstractTill now, AIDS, caused by the human immunodeficiency virus (HIV) is still a severe health problem worldwide. It weakens the immune system by targeting the T-helper cells. Specifically, the severity of the pandemic HIV-1 makes the emergence of an enduring effective vaccine against HIV-1. Therefore, we have applied a series of immunoinformatics approaches to the four conserved domains of HIV-1 integrase (IN) proteins to design an effective multi-epitope based subunit vaccine which mig...
Source: Microbial Pathogenesis - Category: Infectious Diseases Source Type: research
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: African Health | AIDS Vaccine | Health | HIV AIDS | Vaccines